NRX Pharmaceuticals (NRXP) Return on Capital Employed (2018 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Return on Capital Employed of 134.31% for Q1 2026, up 7404.0% year-over-year from 1.79% in Q1 2025, and up 20.88% quarter-over-quarter from 111.11% in Q4 2025.
NRX Pharmaceuticals (NRXP) Return on Capital Employed (2018 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Return on Capital Employed for 9 consecutive years, with 134.31% the latest figure, recorded in Q1 2026.
- In Q1 2026, Return on Capital Employed rose 7404.0% year-over-year to 134.31%; the TTM figure through Mar 2026 stood at 134.31% (up 7404.0% YoY), while the FY2025 annual figure was 80.02%, down 3293.0% from the prior year.
- Return on Capital Employed rose to 134.31% in Q1 2026 per NRXP's latest filing, from 111.11% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 1704.47% in Q2 2023 and bottomed at 1872.9% in Q1 2023.
- Historically, Return on Capital Employed has averaged 101.76% across 5 years, with a median of 107.51% in 2025.
- Annual changes were most pronounced in 2023 — Return on Capital Employed jumped 70722 bps — and 2024, when it slumped 83443 bps.
- NRX Pharmaceuticals' Return on Capital Employed stood at 455.41% in 2022, then surged by 155 bps to 251.81% in 2023, then plunged by 59 bps to 103.91% in 2024, then advanced by 7 bps to 111.11% in 2025, then rose by 21 bps to 134.31% in 2026.
- Business Quant data shows NRXP's Return on Capital Employed at 134.31% in Q1 2026, 111.11% in Q4 2025, and 45.75% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | 183.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 134.31% |
| Dec 31, 2025 | 111.11% |
| Sep 30, 2025 | 45.75% |
| Jun 30, 2025 | 38.06% |
| Mar 31, 2025 | 60.27% |
| Dec 31, 2024 | 103.91% |
| Sep 30, 2024 | 132.65% |
| Dec 31, 2023 | 251.81% |
| Sep 30, 2023 | 967.08% |
| Jun 30, 2023 | 1,704.47% |
| Mar 31, 2023 | -1,872.90% |
| Dec 31, 2022 | -455.41% |
| Dec 31, 2021 | -427.82% |
| Sep 30, 2021 | 2,216.18% |
| Jun 30, 2021 | 204.32% |
| Dec 31, 2020 | 120.66% |
| Sep 30, 2020 | -92.72% |
| Jun 30, 2020 | -6.50% |
| Mar 31, 2020 | -3.55% |
| Dec 31, 2019 | -1.97% |